Vico's VO659 Receives EC's Orphan Drug Designation for Spinocerebellar Ataxia
Shots:
- The EC granted ODD for VO659 for the treatment of spinocerebellar ataxia (SCA). The ODD was based on a EMA’s COMP positive opinion
- The company previously received ODD in Huntington Disease The company focused on the development of RNA modulating therapies for rare neurological disorders
- VO659 is an antisense oligonucleotide product- designed to suppress mutant proteins and slow or halt disease progression
Ref: PRNewswire | Image: Polaris Partners
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com